

Assessment of Hydroxychloroquine and Chloroquine Safety Profiles – A Systematic Review and Meta-Analysis


Lu Ren¹, MD, Wilson Xu¹, BS, James L Overton¹, MS, Shandong Yu³, MD, PhD,
Nipavan Chiamvimonvat^{1,2}, MD, and Phung N. Thai¹, PhD

¹Department of Internal Medicine, Cardiology, UC Davis; ²Department of Veteran Affairs;
³Department of Cardiology, Cardiovascular Center, Beijing Friendship Hospital, Capital Medical
University, Beijing


Corresponding authors:

Phung N. Thai and Nipavan Chiamvimonvat
Division of Cardiovascular Medicine
University of California, Davis
451 Health Science Drive, GBSF 6315
Davis, CA 95616
Department of Veterans Affairs, Northern California Health Care System
10535 Hospital Way
Mather, CA 95655
Emails: pnthai@ucdavis.edu; ncchiamvimonvat@ucdavis.edu

Supplementary Figures




Supplementary Figure 1. A) Meta-regression analyses of mild and B) severe AEs with respect to age, duration, and dosage.










Supplementary Figure 2. Funnel plots showing publication bias for mild, severe, total AEs, and withdrawals due to AEs.

Chloroquine




Hydroxychloroquine



Supplementary Figure 3. Funnel plots showing publication bias for neurologic, gastrointestinal, dermatologic, and ophthalmic AEs.


Chloroquine

Hydroxychloroquine










Supplementary Figure 4. L'Abbé Plots examining heterogeneity for mild AEs, severe AEs, total AEs, and withdrawals due to AEs.

Chloroquine



Hydroxychloroquine



Supplementary Figure 5. L'Abbé Plots examining heterogeneity for neurologic, gastrointestinal, dermatologic, and ophthalmic AEs.

Supplementary Table 1. Risk of Bias Assessment

Chloroquine Studies							
Study	Random Sequence Generation	Allocation Concealment	Selective Reporting	Other Sources of Bias	Blinding (Participants and Personnel)	Blinding (Outcome Assessment)	Incomplete Outcome Data
*Arnaout et al. (2019)	LR	UR	LR	LR	LR	UR	LR
*Terrabuio et al. (2018)	LR	LR	LR	UR	LR	LR	LR
*Borges et al. (2013)	UR	UR	LR	UR	LR	UR	LR
*Paton et al. (2011)	LR	LR	LR	LR	LR	LR	LR
*Tricou et al. (2010)	LR	LR	LR	LR	LR	LR	LR
*De Lamballerie et al. (2009)	UR	UR	HR	UR	UR	UR	UR
Hydroxychloroquine Studies							
Study	Random Sequence Generation	Allocation Concealment	Selective Reporting	Other Sources of Bias	Blinding (Participants and Personnel)	Blinding (Outcome Assessment)	Incomplete Outcome Data
*Chen et al. (2020)	LR	LR	LR	LR	LR	LR	LR
*Boonpiyathad et al. (2017)	LR	LR	LR	LR	HR	UR	LR
*Wasko et al. (2016)	LR	LR	LR	LR	LR	LR	LR
*Gottenberg et al. (2014)	LR	LR	LR	LR	LR	LR	LR
*Solomon et al. (2014)	LR	LR	LR	LR	LR	LR	LR
*Rotaru et al. (2014)	LR	LR	LR	LR	LR	UR	UR
*Paton et al. (2012)	LR	LR	LR	LR	LR	LR	LR
*Fong et al. (2007)	LR	LR	LR	LR	LR	LR	LR
*Gerstein et al. (2001)	LR	LR	LR	LR	LR	LR	LR
*Van Gool et al. (2001)	LR	LR	LR	LR	LR	LR	LR
*Sperber et al. (1995)	LR	LR	LR	LR	LR	LR	LR
*The HERA Study Group (1995)	LR	LR	LR	LR	LR	LR	LR
*Clark et al. (1993)	LR	LR	LR	LR	LR	LR	LR
*Kruize et al. (1993)	LR	LR	LR	LR	LR	LR	LR

Supplementary Table 1. LR = low risk, UR = unclear risk, HR = high risk